http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180065684-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff283c7d6797987f01db547f606e6b32 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2561-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2531-113 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2016-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc03cc6d8eace30459b32e5831ac143f |
| publicationDate | 2018-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20180065684-A |
| titleOfInvention | The diagnosis bio-marker for predicting the emergence of castration-resistance in prostate cancer |
| abstract | The present invention relates to a composition for diagnostic biomarkers for predicting hormone refractory appearance in prostate cancer. The present invention relates to a primer having the nucleotide sequence of SEQ ID NO: 1 in the forward direction and a primer having the nucleotide sequence of SEQ ID NO: 2 in the reverse direction to the primer having the nucleotide sequence of SEQ ID NO: 1 in the forward direction among the cDNAs corresponding to the LPAR1 mRNA in the high- The primer having the nucleotide sequence of SEQ ID NO: 4 in the reverse direction to the primer or the primer having the nucleotide sequence of SEQ ID NO: 4 in the reverse direction to the primer having the nucleotide sequence of SEQ ID NO: 5 in the forward direction was predicted by the qPCR method Wherein the biomarker is a diagnostic biomarker composition. According to the present invention, it is possible to provide a diagnostic biomarker composition capable of predicting the occurrence of hormone refractory irrespective of the CCM1 signal transduction mechanism in prostate cancer. Therefore, it is possible to provide a diagnostic biomarker composition which can not be found in a diagnostic method using CCM1 as a biomarker, It is possible to diagnose the appearance complementarily. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220160259-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022250465-A1 |
| priorityDate | 2016-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 234.